相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
Junjie Wu et al.
CANCER LETTERS (2018)
Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: key role of interleukin-6
Clelia Madeddu et al.
HAEMATOLOGICA (2018)
Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: key role of interleukin-6
Clelia Madeddu et al.
HAEMATOLOGICA (2018)
Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment
Bing Feng et al.
ADVANCED MATERIALS (2018)
Improved Cancer Immunochemotherapy via Optimal Co-delivery of Chemotherapeutic and Immunomodulatory Agents
Yichao Chen et al.
MOLECULAR PHARMACEUTICS (2018)
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
Lieve Brochez et al.
EUROPEAN JOURNAL OF CANCER (2017)
Advances in indoleamine 2,3-dioxygenase 1 medicinal chemistry
Alice Coletti et al.
MEDCHEMCOMM (2017)
Structural insights into the binding mechanism of IDO1 with hydroxylamidine based inhibitor INCB14943
You Wu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1
Yi-Hui Peng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy
Xiao Zhao et al.
BIOMATERIALS (2016)
Immunization with functionalized carbon nanotubes enhances the antibody response against mode antigen ovalbumin
Xinfeng Zhu et al.
IMMUNOLOGY LETTERS (2016)
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2016)
An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy
Yichao Chen et al.
NATURE COMMUNICATIONS (2016)
Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies?
Cedric Rebe et al.
FUTURE ONCOLOGY (2015)
Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum
Jigang Wang et al.
NATURE COMMUNICATIONS (2015)
Synthesis and evaluation of the antiplasmodial activity of tryptanthrin derivatives
Liliane Abodo Onambele et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE (2015)
The synthetic Tryptanthrin analogue suppresses STATs signalling and induces caspase dependent apoptosis via ERK up regulation in human leukemia HL-60 cells
A. Pathania et al.
EUROPEAN JOURNAL OF CANCER (2014)
Phagocytic Uptake of Oxidized Heme Polymer Is Highly Cytotoxic to Macrophages
Rohitas Deshmukh et al.
PLOS ONE (2014)
Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2,3-Dioxygenase with Therapeutic Activity in Lewis Lung Cancer (LLC) Tumor-Bearing Mice
Shuangshuang Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Tryptanthrin-Loaded Nanoparticles for Delivery into Cultured Human Breast Cancer Cells, MCF7: the Effects of Solid Lipid/Liquid Lipid Ratios in the Inner Core
Yi-Ping Fang et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2011)
Iron trafficking and metabolism in macrophages: contribution to the polarized phenotype
Gaetano Cairo et al.
TRENDS IN IMMUNOLOGY (2011)
Cytotoxicity and reversal of multidrug resistance by tryptanthrin-derived indoloquinazolines
Sung-tsai Yu et al.
ACTA PHARMACOLOGICA SINICA (2010)
Antitumor and antimetastatic activities of chloroquine diphosphate in a murine model of breast cancer
Pei-Du Jiang et al.
BIOMEDICINE & PHARMACOTHERAPY (2010)
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Xiangdong Liu et al.
BLOOD (2010)
Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model
Eddy W. Yue et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Nanoparticle therapeutics: an emerging treatment modality for cancer
Mark E. Davis et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells
Sung-Tsai Yu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses
De-Yan Hou et al.
CANCER RESEARCH (2007)
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
DE Owens et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2006)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase
DH Munn et al.
SCIENCE (2002)
Novel indolo[2,1-b]quinazoline analogues as cytostatic agents:: Synthesis, biological evaluation and structure-activity relationship
VM Sharma et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2002)
Cell differentiation and apoptosis of monocytic and promyelocytic leukemia cells (U-937 and HL-60) by tryptanthrin, an active ingredient of Polygonum tinctorium Lour.
T Kimoto et al.
PATHOLOGY INTERNATIONAL (2001)
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
H Maeda et al.
JOURNAL OF CONTROLLED RELEASE (2000)
分享论文
